Global Breast cancer Market

The secondary research process involved comprehensive analysis of regulatory databases, peer-reviewed oncology journals, clinical trial repositories, and authoritative cancer research organizations. Key sources included the US Food & Drug Administration (FDA), European Medicines Agency (EMA), China National Medical Products Administration (NMPA), Pharmaceuticals and Medical Devices Agency (PMDA) Japan, National Cancer Institute (NCI/NIH), Surveillance, Epidemiology, and End Results Program (SEER), Centers for Disease Control and Prevention (CDC) National Program of Cancer Registries, World Health Organization (WHO) International Agency for Research on Cancer (IARC), American Cancer Society (ACS) Cancer Statistics Center, Breastcancer.org Clinical Research Database, Susan G. Komen Foundation Research Portal, ClinicalTrials.gov, National Comprehensive Cancer Network (NCCN) Guidelines Database, European Society for Medical Oncology (ESMO) Clinical Practice Guidelines, American Society of Clinical Oncology (ASCO) Research Archive, PubMed/MEDLINE, The Lancet Oncology, Journal of Clinical Oncology, JAMA Oncology, Breast Cancer Research and Treatment, and IQVIA National Sales Perspectives. These sources were used to collect incidence and mortality statistics, regulatory approval pathways for oncology therapeutics, clinical trial efficacy data, biomarker prevalence rates, and reimbursement policies for taxanes, anthracyclines, monoclonal antibodies, and emerging immunotherapies.

Supply-side and demand-side stakeholders were interviewed during the primary research process to acquire qualitative and quantitative insights regarding pipeline development, clinical adoption, and treatment protocols. From biopharmaceutical manufacturers, oncology-focused biotech firms, and diagnostic imaging companies, supply-side sources included Chief Medical Officers, Heads of Oncology R&D, Oncology Business Unit Presidents, and Regulatory Strategy Directors. Medical oncologists, breast cancer surgeons, radiation oncologists, oncology pharmacists, hospital pharmacy directors, and procurement lead from National Cancer Institute-designated cancer centers, comprehensive community cancer programs, academic medical centers, and outpatient infusion clinics comprised demand-side sources. The primary research validated treatment modality preferences across disease stages, confirmed biosimilar adoption timelines, and gathered insights on payor restrictions, formulary positioning, and patient assistance program utilization.

Primary Respondent Breakdown:

By Designation: C-level Primaries (28%), Director Level (35%), Others (37%)

By Region: North America (32%), Europe (29%), Asia-Pacific (34%), Rest of World (5%)

Global market valuation was derived through revenue aggregation and treatment episode analysis across curative and palliative care settings. The methodology included:

Identification of 48+ key biopharmaceutical manufacturers and biosimilar developers across North America, Europe, Asia-Pacific, Latin America, and Middle East/Africa

Therapeutic mapping across chemotherapy (taxanes, anthracyclines), hormonal therapy (SERMs, aromatase inhibitors), targeted therapy (HER2 inhibitors, CDK4/6 inhibitors), and immunotherapy (checkpoint inhibitors) segments

Analysis of reported and modeled annual oncology revenues specific to breast cancer portfolios, including neoadjuvant, adjuvant, and metastatic treatment lines

Coverage of manufacturers representing 72-78% of global market share in 2024

Extrapolation using bottom-up (incidence cases × treatment penetration × ASP by country/therapy type) and top-down (pharmaceutical revenue validation against national health expenditure data) approaches to derive segment-specific valuations for stage-specific interventions and drug class distributions